Immune Thrombocytopenic Purpura (ITP) Treatment Guidelines
Immune thrombocytopenic purpura (ITP) is an acquired autoimmune bleeding disorder characterized by isolated low platelet counts (thrombocytopenia) and an increased risk of bleeding. ITP can occur in both children and adults, with varying clinical manifestations and treatment approaches based on patient factors. This article provides an overview of the latest immune thrombocytopenic purpura treatment guidelines for effectively managing ITP in pediatric and adult populations while optimizing patient safety and quality of life. Diagnosis and Prognosis Accurately diagnosing ITP ensures patients receive appropriate care while avoiding unnecessary treatments or costs. Key diagnostic criteria include: Isolated thrombocytopenia – Platelet count under 100 x 109/L Normal hemoglobin, leukocyte and red cell indices – Rules out other causes of low platelets Careful review of medications, medical history and physical examination – To exclude secondary ITP triggers like infection or auto